Prelude Therapeutics (PRLD) Profit After Tax Growth (3y) (2022 - 2026)

Prelude Therapeutics (PRLD) Profit After Tax Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.53%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -27.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 70.25%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Prelude Therapeutics 322.24 Mn 177.64 Mn - 27.80%

Historic Data

Download Data
DateValue
Mar 31, 2026 27.80%
Dec 31, 2025 16.26%
Sep 30, 2025 13.07%
Jun 30, 2025 -4.49%
Mar 31, 2025 -2.90%
Dec 31, 2024 4.15%
Sep 30, 2024 -1.50%
Jun 30, 2024 -8.95%
Mar 31, 2024 -13.85%
Dec 31, 2023 -18.76%
Sep 30, 2023 -22.23%
Jun 30, 2023 -38.69%
Mar 31, 2023 -42.84%
Dec 31, 2022 -40.71%
Sep 30, 2022 -64.59%